Case Report: Collagen Matrix with Polyhexamethylene Biguanide and Dermagraft for Patient with Chronic Heel Ulcerations.

Mark Graeber DPM   Podiatry Resident DVA Miami FL. Medical Center

PATIENT HISTORY / METHODS /RESULTS

History: 67 yo IDDM nursing home resident with PMH of HLD, dementia and DM2. Pt has had b/l chronic heel ulcerations for greater than 2 years and is wheelchair bound. Pt has had difficulty with offloading modalities and compliance. Standard wound care has been given including second tier treatments without any significant results. Imaging is negative for OM as per serial x-rays and Pt has adequate blood flow as per ABI. Off loading boots properly used to facilitate offloading.

Methods: Standard of care wound debridement weekly and applications of Collagen Matrix with polyhexamethylene biguanide (PuraPly AM) and Dermagraft.

Results: After 7 applications of Collagen matrix with PHMB, and 5 applications of Dermagraft at 4 weeks R wound showed a 64.1% and L wound showed a 52.9% reduction. Pt had a total reduction of 96.7% on the R foot and 100% on the L foot at 12 weeks.

WOUND PROGRESS:

Left

Right

CONCLUSION

 This particular Pt has chronic wounds that have proved difficult to heal and have failed application of other wound care products in the past. PuraPly AM utilizes purified Type 1 collagen and PHMB for microbial barrier. Due to the chronic nature of this Pt wounds it is likely that the bio burden had placed a healing barrier. Along with proper offloading, PuraPly AM and Dermagraft improved wound bed appearance and size in our Pt. As seen from the results, the application of PuraPly AM has enable improvement where other products have failed. PuraPly AM proved to be an efficacious option for assistance in healing of chronic wounds. (Unfortunately, due to continued offloading issues the Pt has since re ulcerated the wounds).

SOURCES

Mulder GD, Cavorsi JP, Lee DK. Wounds. 2007;19(7):173-182.   Wolcott R, Dowd S. Plast Reconstr Surg. 2011;127(suppl 1):28S-35S. .   Butcher M. BJN, 2012; 21(12 Tissue Viability Supplement):S16-S21